View ValuationBCWORLD PHARM 将来の成長Future 基準チェック /06現在、 BCWORLD PHARMの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長20.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Feb 13BCWORLD PHARM. Co., Ltd., Annual General Meeting, Mar 26, 2026BCWORLD PHARM. Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 22, geumto-ro 40-gil, sujeong-gu, gyeonggi-do, seongnam South KoreaDeclared Dividend • Dec 13Dividend of ₩100.00 announcedShareholders will receive a dividend of ₩100.00. Ex-date: 29th December 2025 Payment date: 1st January 1970 Dividend yield will be 1.9%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (139% cash payout ratio). The dividend has increased by an average of 2.8% per year over the past 7 years and payments have been stable during that time.分析記事 • Dec 12BCWORLD PHARM. Co., Ltd.'s (KOSDAQ:200780) Popularity With Investors Is Under Threat From OverpricingThere wouldn't be many who think BCWORLD PHARM. Co., Ltd.'s ( KOSDAQ:200780 ) price-to-sales (or "P/S") ratio of 0.6x...お知らせ • Dec 12BCWORLD PHARM. Co., Ltd. announces Annual dividendBCWORLD PHARM. Co., Ltd. announced Annual dividend of KRW 100.0000 per share, ex-date on December 29, 2025 and record date on December 31, 2025.New Risk • Nov 28New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. Cash payout ratio: 126% Dividend yield: 2.0% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.8x net interest cover). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 126% Earnings have declined by 3.8% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩38.0b market cap, or US$25.9m).Buy Or Sell Opportunity • Nov 11Now 20% undervaluedOver the last 90 days, the stock has risen 7.2% to ₩4,680. The fair value is estimated to be ₩5,857, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 76%.New Risk • Aug 29New major risk - Revenue and earnings growthEarnings have declined by 1.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.8x net interest cover). Earnings have declined by 1.8% per year over the past 5 years. Minor Risks Paying a dividend despite being loss-making. Market cap is less than US$100m (₩41.0b market cap, or US$29.5m).Reported Earnings • Mar 15Full year 2024 earnings released: ₩525 loss per share (vs ₩312 profit in FY 2023)Full year 2024 results: ₩525 loss per share (down from ₩312 profit in FY 2023). Revenue: ₩74.8b (flat on FY 2023). Net loss: ₩4.43b (down 268% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.お知らせ • Feb 14BCWORLD PHARM. Co., Ltd., Annual General Meeting, Mar 28, 2025BCWORLD PHARM. Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 22, geumto-ro 40beon-gil, sujeong-gu, gyeonggi-do, seongnam South Korea分析記事 • Jan 03Revenues Not Telling The Story For BCWORLD PHARM. Co., Ltd. (KOSDAQ:200780) After Shares Rise 30%BCWORLD PHARM. Co., Ltd. ( KOSDAQ:200780 ) shareholders would be excited to see that the share price has had a great...New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩39.7b market cap, or US$27.6m).分析記事 • Dec 04Does BCWORLD PHARM (KOSDAQ:200780) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • May 19First quarter 2024 earnings released: ₩184 loss per share (vs ₩27.00 profit in 1Q 2023)First quarter 2024 results: ₩184 loss per share (down from ₩27.00 profit in 1Q 2023). Revenue: ₩16.3b (down 15% from 1Q 2023). Net loss: ₩1.55b (down ₩1.77b from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 111% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.分析記事 • Mar 18Investors Shouldn't Be Too Comfortable With BCWORLD PHARM's (KOSDAQ:200780) EarningsDespite posting some strong earnings, the market for BCWORLD PHARM. Co., Ltd.'s ( KOSDAQ:200780 ) stock hasn't moved...Reported Earnings • Mar 15Full year 2023 earnings released: EPS: ₩312 (vs ₩33.00 in FY 2022)Full year 2023 results: EPS: ₩312 (up from ₩33.00 in FY 2022). Revenue: ₩75.1b (up 3.3% from FY 2022). Net income: ₩2.63b (up ₩2.35b from FY 2022). Profit margin: 3.5% (up from 0.4% in FY 2022). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.Upcoming Dividend • Dec 20Upcoming dividend of ₩100.00 per share at 1.6% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).Reported Earnings • Nov 17Third quarter 2023 earnings released: EPS: ₩10.00 (vs ₩59.00 loss in 3Q 2022)Third quarter 2023 results: EPS: ₩10.00 (up from ₩59.00 loss in 3Q 2022). Revenue: ₩17.6b (flat on 3Q 2022). Net income: ₩87.3m (up ₩588.8m from 3Q 2022). Profit margin: 0.5% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Upcoming Dividend • Dec 21Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 27 April 2023. Payout ratio is a comfortable 75% but the company is not cash flow positive. Trailing yield: 1.2%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: ₩33.00 (vs ₩194 loss in 2Q 2021)Second quarter 2022 results: EPS: ₩33.00 (up from ₩194 loss in 2Q 2021). Revenue: ₩18.5b (up 20% from 2Q 2021). Net income: ₩282.2m (up ₩1.94b from 2Q 2021). Profit margin: 1.5% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Aug 17Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to ₩8,300, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 31% over the past three years.Reported Earnings • Mar 16Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: ₩360 (down from ₩548 in FY 2020). Revenue: ₩61.6b (up 8.2% from FY 2020). Net income: ₩3.07b (down 34% from FY 2020). Profit margin: 5.0% (down from 8.2% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Dec 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is a comfortable 27% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (2.4%). In line with average of industry peers (0.8%).Valuation Update With 7 Day Price Move • Aug 25Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩21,750, the stock trades at a trailing P/E ratio of 55.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 14% over the past three years.Valuation Update With 7 Day Price Move • Aug 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩22,350, the stock trades at a trailing P/E ratio of 44.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 7.7% over the past three years.Reported Earnings • May 11First quarter 2021 earnings released: EPS ₩132 (vs ₩176 in 1Q 2020)The company reported a poor first quarter result with weaker earnings and profit margins, although revenues were flat. First quarter 2021 results: Revenue: ₩14.6b (flat on 1Q 2020). Net income: ₩1.13b (down 25% from 1Q 2020). Profit margin: 7.7% (down from 10% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩19,700, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 27x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 16% over the past three years.Is New 90 Day High Low • Mar 08New 90-day low: ₩17,250The company is down 21% from its price of ₩21,850 on 08 December 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 23% over the same period.分析記事 • Mar 01BCWORLD PHARM (KOSDAQ:200780) Seems To Be Using A Lot Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Feb 27Full year 2020 earnings released: EPS ₩548 (vs ₩712 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: ₩56.9b (up 10% from FY 2019). Net income: ₩4.66b (down 23% from FY 2019). Profit margin: 8.2% (down from 12% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.お知らせ • Feb 26BCWORLD PHARM. Co., Ltd., Annual General Meeting, Mar 12, 2021BCWORLD PHARM. Co., Ltd., Annual General Meeting, Mar 12, 2021, at 09:00 Korea Standard Time.分析記事 • Feb 09Does The Market Have A Low Tolerance For BCWORLD PHARM. Co., Ltd.'s (KOSDAQ:200780) Mixed Fundamentals?With its stock down 18% over the past month, it is easy to disregard BCWORLD PHARM (KOSDAQ:200780). We, however decided...Is New 90 Day High Low • Feb 09New 90-day low: ₩19,350The company is down 6.0% from its price of ₩20,650 on 11 November 2020. The South Korean market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.分析記事 • Jan 25Is BCWORLD PHARM. Co., Ltd. (KOSDAQ:200780) A Good Dividend Stock?Could BCWORLD PHARM. Co., Ltd. ( KOSDAQ:200780 ) be an attractive dividend share to own for the long haul? Investors...分析記事 • Jan 11If You Had Bought BCWorld Pharm (KOSDAQ:200780) Stock A Year Ago, You Could Pocket A 75% Gain TodayThese days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But you can...分析記事 • Dec 26Do Insiders Own Lots Of Shares In BCWorld Pharm Co., Ltd. (KOSDAQ:200780)?Every investor in BCWorld Pharm Co., Ltd. ( KOSDAQ:200780 ) should be aware of the most powerful shareholder groups...Valuation Update With 7 Day Price Move • Dec 22Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩26,550, the stock is trading at a trailing P/E ratio of 43.4x, up from the previous P/E ratio of 37.3x. This compares to an average P/E of 32x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 38%.Is New 90 Day High Low • Dec 18New 90-day high: ₩25,750The company is up 22% from its price of ₩21,150 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩25,750, the stock is trading at a trailing P/E ratio of 42.1x, up from the previous P/E ratio of 36.4x. This compares to an average P/E of 30x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 34%.分析記事 • Dec 08Are BCWorld Pharm's (KOSDAQ:200780) Statutory Earnings A Good Guide To Its Underlying Profitability?Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...分析記事 • Nov 18Is BCWorld Pharm (KOSDAQ:200780) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Is New 90 Day High Low • Oct 08New 90-day high: ₩23,950The company is up 32% from its price of ₩18,150 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、BCWORLD PHARM は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A200780 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202679,812-2,510-3,0822,170N/A12/31/202575,800-4,8971,5725,577N/A9/30/202577,044-3,7656084,118N/A6/30/202575,316-3,7434,2166,620N/A3/31/202574,334-4,9374,1426,218N/A12/31/202474,814-4,4331,6344,042N/A9/30/202472,884-8,0754,5917,185N/A6/30/202472,959-6,8974,5417,289N/A3/31/202472,1958596,3299,326N/A12/31/202375,1112,6348,22910,938N/A9/30/202376,0566,2409,96213,879N/A6/30/202376,2135,6516,75710,549N/A3/31/202376,0404814,5309,594N/A12/31/202272,7032816196,883N/A9/30/202268,918255-9,2401,469N/A6/30/202266,489-644-12,2882,717N/A3/31/202263,383-2,944-17,649-2,572N/A12/31/202162,079-1,843-19,266-620N/A9/30/202159,217-8,508-14,908-1,183N/A6/30/202157,763-6,032-13,577-8,405N/A3/31/202157,071-1,956-14,431-5,022N/A12/31/202057,030-1,580-13,099-5,502N/A9/30/202056,434-2,450-11,0788,902N/A6/30/202056,034-1,392-13,2709,815N/A3/31/202054,135-1,972-7,59211,905N/A12/31/201951,497-1,553N/A12,110N/A9/30/201951,4405,011N/A-783N/A6/30/201952,4924,761N/A6,948N/A3/31/201953,8235,024N/A4,464N/A12/31/201854,7924,993N/A5,287N/A9/30/201854,7227,777N/A6,710N/A6/30/201853,0448,124N/A5,265N/A3/31/201851,0088,000N/A7,599N/A12/31/201750,2078,083N/A7,900N/A12/31/201645,6586,475N/A244N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A200780の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A200780の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A200780の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A200780の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A200780の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A200780の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 03:28終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BCWORLD PHARM. Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Feb 13BCWORLD PHARM. Co., Ltd., Annual General Meeting, Mar 26, 2026BCWORLD PHARM. Co., Ltd., Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 22, geumto-ro 40-gil, sujeong-gu, gyeonggi-do, seongnam South Korea
Declared Dividend • Dec 13Dividend of ₩100.00 announcedShareholders will receive a dividend of ₩100.00. Ex-date: 29th December 2025 Payment date: 1st January 1970 Dividend yield will be 1.9%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (139% cash payout ratio). The dividend has increased by an average of 2.8% per year over the past 7 years and payments have been stable during that time.
分析記事 • Dec 12BCWORLD PHARM. Co., Ltd.'s (KOSDAQ:200780) Popularity With Investors Is Under Threat From OverpricingThere wouldn't be many who think BCWORLD PHARM. Co., Ltd.'s ( KOSDAQ:200780 ) price-to-sales (or "P/S") ratio of 0.6x...
お知らせ • Dec 12BCWORLD PHARM. Co., Ltd. announces Annual dividendBCWORLD PHARM. Co., Ltd. announced Annual dividend of KRW 100.0000 per share, ex-date on December 29, 2025 and record date on December 31, 2025.
New Risk • Nov 28New major risk - Dividend sustainabilityThe dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. Cash payout ratio: 126% Dividend yield: 2.0% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.8x net interest cover). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 126% Earnings have declined by 3.8% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩38.0b market cap, or US$25.9m).
Buy Or Sell Opportunity • Nov 11Now 20% undervaluedOver the last 90 days, the stock has risen 7.2% to ₩4,680. The fair value is estimated to be ₩5,857, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 76%.
New Risk • Aug 29New major risk - Revenue and earnings growthEarnings have declined by 1.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.8x net interest cover). Earnings have declined by 1.8% per year over the past 5 years. Minor Risks Paying a dividend despite being loss-making. Market cap is less than US$100m (₩41.0b market cap, or US$29.5m).
Reported Earnings • Mar 15Full year 2024 earnings released: ₩525 loss per share (vs ₩312 profit in FY 2023)Full year 2024 results: ₩525 loss per share (down from ₩312 profit in FY 2023). Revenue: ₩74.8b (flat on FY 2023). Net loss: ₩4.43b (down 268% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 14BCWORLD PHARM. Co., Ltd., Annual General Meeting, Mar 28, 2025BCWORLD PHARM. Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 22, geumto-ro 40beon-gil, sujeong-gu, gyeonggi-do, seongnam South Korea
分析記事 • Jan 03Revenues Not Telling The Story For BCWORLD PHARM. Co., Ltd. (KOSDAQ:200780) After Shares Rise 30%BCWORLD PHARM. Co., Ltd. ( KOSDAQ:200780 ) shareholders would be excited to see that the share price has had a great...
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩39.7b market cap, or US$27.6m).
分析記事 • Dec 04Does BCWORLD PHARM (KOSDAQ:200780) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • May 19First quarter 2024 earnings released: ₩184 loss per share (vs ₩27.00 profit in 1Q 2023)First quarter 2024 results: ₩184 loss per share (down from ₩27.00 profit in 1Q 2023). Revenue: ₩16.3b (down 15% from 1Q 2023). Net loss: ₩1.55b (down ₩1.77b from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 111% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
分析記事 • Mar 18Investors Shouldn't Be Too Comfortable With BCWORLD PHARM's (KOSDAQ:200780) EarningsDespite posting some strong earnings, the market for BCWORLD PHARM. Co., Ltd.'s ( KOSDAQ:200780 ) stock hasn't moved...
Reported Earnings • Mar 15Full year 2023 earnings released: EPS: ₩312 (vs ₩33.00 in FY 2022)Full year 2023 results: EPS: ₩312 (up from ₩33.00 in FY 2022). Revenue: ₩75.1b (up 3.3% from FY 2022). Net income: ₩2.63b (up ₩2.35b from FY 2022). Profit margin: 3.5% (up from 0.4% in FY 2022). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Dec 20Upcoming dividend of ₩100.00 per share at 1.6% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 29 April 2024. Payout ratio is a comfortable 14% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).
Reported Earnings • Nov 17Third quarter 2023 earnings released: EPS: ₩10.00 (vs ₩59.00 loss in 3Q 2022)Third quarter 2023 results: EPS: ₩10.00 (up from ₩59.00 loss in 3Q 2022). Revenue: ₩17.6b (flat on 3Q 2022). Net income: ₩87.3m (up ₩588.8m from 3Q 2022). Profit margin: 0.5% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Dec 21Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 27 April 2023. Payout ratio is a comfortable 75% but the company is not cash flow positive. Trailing yield: 1.2%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).
Reported Earnings • Sep 01Second quarter 2022 earnings released: EPS: ₩33.00 (vs ₩194 loss in 2Q 2021)Second quarter 2022 results: EPS: ₩33.00 (up from ₩194 loss in 2Q 2021). Revenue: ₩18.5b (up 20% from 2Q 2021). Net income: ₩282.2m (up ₩1.94b from 2Q 2021). Profit margin: 1.5% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Aug 17Investor sentiment deteriorated over the past weekAfter last week's 24% share price decline to ₩8,300, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 23x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 31% over the past three years.
Reported Earnings • Mar 16Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: ₩360 (down from ₩548 in FY 2020). Revenue: ₩61.6b (up 8.2% from FY 2020). Net income: ₩3.07b (down 34% from FY 2020). Profit margin: 5.0% (down from 8.2% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Dec 22Upcoming dividend of ₩100.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is a comfortable 27% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (2.4%). In line with average of industry peers (0.8%).
Valuation Update With 7 Day Price Move • Aug 25Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩21,750, the stock trades at a trailing P/E ratio of 55.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 14% over the past three years.
Valuation Update With 7 Day Price Move • Aug 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩22,350, the stock trades at a trailing P/E ratio of 44.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 7.7% over the past three years.
Reported Earnings • May 11First quarter 2021 earnings released: EPS ₩132 (vs ₩176 in 1Q 2020)The company reported a poor first quarter result with weaker earnings and profit margins, although revenues were flat. First quarter 2021 results: Revenue: ₩14.6b (flat on 1Q 2020). Net income: ₩1.13b (down 25% from 1Q 2020). Profit margin: 7.7% (down from 10% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₩19,700, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 27x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 16% over the past three years.
Is New 90 Day High Low • Mar 08New 90-day low: ₩17,250The company is down 21% from its price of ₩21,850 on 08 December 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 23% over the same period.
分析記事 • Mar 01BCWORLD PHARM (KOSDAQ:200780) Seems To Be Using A Lot Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Feb 27Full year 2020 earnings released: EPS ₩548 (vs ₩712 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: ₩56.9b (up 10% from FY 2019). Net income: ₩4.66b (down 23% from FY 2019). Profit margin: 8.2% (down from 12% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 26BCWORLD PHARM. Co., Ltd., Annual General Meeting, Mar 12, 2021BCWORLD PHARM. Co., Ltd., Annual General Meeting, Mar 12, 2021, at 09:00 Korea Standard Time.
分析記事 • Feb 09Does The Market Have A Low Tolerance For BCWORLD PHARM. Co., Ltd.'s (KOSDAQ:200780) Mixed Fundamentals?With its stock down 18% over the past month, it is easy to disregard BCWORLD PHARM (KOSDAQ:200780). We, however decided...
Is New 90 Day High Low • Feb 09New 90-day low: ₩19,350The company is down 6.0% from its price of ₩20,650 on 11 November 2020. The South Korean market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.
分析記事 • Jan 25Is BCWORLD PHARM. Co., Ltd. (KOSDAQ:200780) A Good Dividend Stock?Could BCWORLD PHARM. Co., Ltd. ( KOSDAQ:200780 ) be an attractive dividend share to own for the long haul? Investors...
分析記事 • Jan 11If You Had Bought BCWorld Pharm (KOSDAQ:200780) Stock A Year Ago, You Could Pocket A 75% Gain TodayThese days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But you can...
分析記事 • Dec 26Do Insiders Own Lots Of Shares In BCWorld Pharm Co., Ltd. (KOSDAQ:200780)?Every investor in BCWorld Pharm Co., Ltd. ( KOSDAQ:200780 ) should be aware of the most powerful shareholder groups...
Valuation Update With 7 Day Price Move • Dec 22Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩26,550, the stock is trading at a trailing P/E ratio of 43.4x, up from the previous P/E ratio of 37.3x. This compares to an average P/E of 32x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 38%.
Is New 90 Day High Low • Dec 18New 90-day high: ₩25,750The company is up 22% from its price of ₩21,150 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩25,750, the stock is trading at a trailing P/E ratio of 42.1x, up from the previous P/E ratio of 36.4x. This compares to an average P/E of 30x in the Pharmaceuticals industry in South Korea. Total returns to shareholders over the past three years are 34%.
分析記事 • Dec 08Are BCWorld Pharm's (KOSDAQ:200780) Statutory Earnings A Good Guide To Its Underlying Profitability?Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...
分析記事 • Nov 18Is BCWorld Pharm (KOSDAQ:200780) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Is New 90 Day High Low • Oct 08New 90-day high: ₩23,950The company is up 32% from its price of ₩18,150 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period.